Sign in or create an account to add this stock to your watchlist.
About OncoSec Medical (NASDAQ:ONCS)
OncoSec Medical Incorporated, a biotechnology company, engages in developing DNA-based intratumoral immunotherapies in the United States. The company's investigational technology, ImmunoPulseis designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as plasmid encoded IL-12 (tavokinogene telseplasmid or tavo) for the treatment of cancer. Its lead product candidate, ImmunoPulse IL-12, has demonstrated a favorable safety profile, evidence of anti-tumor activity in the treatment of various solid tumors, and the potential to reach beyond the site of local treatment to initiate a systemic immune response in Phase 1 and 2 clinical trials for metastatic melanoma and triple-negative breast cancer. The company has also completed Phase II studies in metastatic melanoma (OMS-I100) and merkel cell carcinoma (OMS-I110). OncoSec Medical Incorporated has an investigator-sponsored clinical trial with the University of California, San Francisco to evaluate the safety and efficacy of ImmunoPulse IL-12 in combination with KEYTRUDA (pembrolizumab) in patients with low tumor-infiltrating lymphocyte (OMS-I102); and a clinical trial collaboration and drug supply agreement with Merck (known as MSD outside the United States and Canada) to evaluate the combination of its ImmuoPulse IL-12 with Merck's anti-PD-1 therapy KEYTRUDA (pembrolizumab) in a registration-directed Phase 2b clinical trial referred to as PISCES. This trial would evaluate the combination of therapies in patients with unresectable metastatic melanoma who have progressed. It also has a research collaboration with Avacta Group plc for gene delivery of therapeutic affimers. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was incorporated in 2008 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ONCS
CUSIPN/A
Phone855-662-6732
Debt
Debt-to-Equity RatioN/A
Current Ratio6.73
Quick Ratio6.73
Price-To-Earnings
Trailing P/E Ratio-1.50
Forward P/E Ratio-2.27
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.49 per share
Price / Book3.24
Profitability
EPS (Most Recent Fiscal Year)($1.06)
Net Income$-21,440,000.00
Net MarginsN/A
Return on Equity-168.58%
Return on Assets-129.10%
Miscellaneous
Employees35
Outstanding Shares51,480,000
OncoSec Medical (NASDAQ:ONCS) Frequently Asked Questions
What is OncoSec Medical's stock symbol?
OncoSec Medical trades on the NASDAQ under the ticker symbol "ONCS."
How were OncoSec Medical's earnings last quarter?
OncoSec Medical (NASDAQ:ONCS) posted its quarterly earnings data on Friday, March, 9th. The biotechnology company reported ($0.24) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.19) by $0.05. View OncoSec Medical's Earnings History.
When is OncoSec Medical's next earnings date?
What price target have analysts set for ONCS?
5 brokers have issued twelve-month price targets for OncoSec Medical's stock. Their predictions range from $4.00 to $5.00. On average, they expect OncoSec Medical's stock price to reach $4.50 in the next year. View Analyst Ratings for OncoSec Medical.
What are Wall Street analysts saying about OncoSec Medical stock?
Here are some recent quotes from research analysts about OncoSec Medical stock:
- 1. Maxim Group analysts commented, "Oncosec announced that the P2b study (PISCES/KEYNOTE-695) in late-stage melanoma evaluating TAVO (DNA-based IL-12, intratumoral) + Keytruda has dosed the first patient." (12/14/2017)
- 2. HC Wainwright analysts commented, "We believe preliminary interim data—based on the first 16-20 patients—could be reported in late 2017 or early 2018. Management have indicated that an ORR of at least 30% would be considered a success for the PISCES study. We note that positive results from the interim analysis may allow the company to apply for Breakthrough Therapy designation in patients who have failed anti- PD-1 monotherapies. In addition, OncoSec may report 24-month follow- up data from the Phase 2 investigator-sponsored trial later this year. In the wake of this update, we reiterate our Buy rating and $6 price target. 43% ORR in Phase 2 combo trial. A prior investigator-sponsored Phase 2 combo study of ImmunoPulse IL-12 and Keytruda in 22 metastatic melanoma patients reported positive data. These patients were predicted to have low likelihoods of response to anti-PD-1 monotherapies based on biomarker assays. The results showed a 43% (9/21) ORR at 24 weeks by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. There were 24% (5/21) complete responders and 19% (4/22) partial responders. Of note, nine out of the 22 patients enrolled had prior checkpoint inhibitor therapy; ORR for this subset of patients was 33% (3/9). The data showed that intra-tumoral electroporation of interleukin-12 DNA, combined with pembrolizumab, can effectively alter the tumor microenvironment and increase tumor- specific CD8+ T-cells, which drive a systemic anti-tumor immune response. The combo therapy had an acceptable safety profile and was well tolerated." (6/2/2017)
Are investors shorting OncoSec Medical?
OncoSec Medical saw a increase in short interest in April. As of April 13th, there was short interest totalling 4,094,692 shares, an increase of 30.6% from the March 30th total of 3,134,350 shares. Based on an average daily trading volume, of 1,698,100 shares, the short-interest ratio is currently 2.4 days. Currently, 8.1% of the shares of the stock are sold short.
Who are some of OncoSec Medical's key competitors?
Some companies that are related to OncoSec Medical include Corium International (CORI), Corvus Pharmaceuticals (CRVS), Seres Therapeutics (MCRB), Durect (DRRX), BioSpecifics Technologies (BSTC), Minerva Neurosciences (NERV), Tyme Technologies (TYME), Biofrontera (BFRA), Sienna Biopharmaceuticals (SNNA), Aquinox Pharmaceuticals (AQXP), Kadmon (KDMN), ArQule (ARQL), Cue Biopharma (CUE), Verastem (VSTM) and CTI BioPharma (CTIC).
Who are OncoSec Medical's key executives?
OncoSec Medical's management team includes the folowing people:
- Dr. Avtar S. Dhillon, Co-Founder & Chairman (Age 57)
- Mr. Punit S. Dhillon BA, Co-Founder, Pres & Director (Age 38)
- Mr. Richard B. Slansky, CFO & Sec. (Age 60)
- Dr. Sharron Gargosky Ph.D., Chief Clinical & Regulatory Officer (Age 54)
- Mr. Daniel J. O'Connor J.D., CEO & Director (Age 54)
Has OncoSec Medical been receiving favorable news coverage?
News articles about ONCS stock have been trending somewhat positive on Sunday, according to Accern Sentiment Analysis. The research firm ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. OncoSec Medical earned a news sentiment score of 0.07 on Accern's scale. They also gave headlines about the biotechnology company an impact score of 47.59 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term.
Who are OncoSec Medical's major shareholders?
OncoSec Medical's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include venBio Select Advisor LLC (7.78%), Point72 Asset Management L.P. (6.25%), Nexthera Capital LP (4.01%), Millennium Management LLC (1.94%), Commonwealth Equity Services LLC (0.15%) and DRW Securities LLC (0.14%). Company insiders that own OncoSec Medical stock include Daniel J O'connor and Punit Dhillon. View Institutional Ownership Trends for OncoSec Medical.
Which institutional investors are buying OncoSec Medical stock?
ONCS stock was purchased by a variety of institutional investors in the last quarter, including venBio Select Advisor LLC, Nexthera Capital LP, Point72 Asset Management L.P., Millennium Management LLC, DRW Securities LLC, Sofinnova Ventures Inc and Commonwealth Equity Services LLC. Company insiders that have bought OncoSec Medical stock in the last two years include Daniel J O'connor and Punit Dhillon. View Insider Buying and Selling for OncoSec Medical.
How do I buy shares of OncoSec Medical?
Shares of ONCS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is OncoSec Medical's stock price today?
One share of ONCS stock can currently be purchased for approximately $1.59.
How big of a company is OncoSec Medical?
OncoSec Medical has a market capitalization of $81.86 million. The biotechnology company earns $-21,440,000.00 in net income (profit) each year or ($1.06) on an earnings per share basis. OncoSec Medical employs 35 workers across the globe.
How can I contact OncoSec Medical?
OncoSec Medical's mailing address is 5820 NANCY RIDGE DRIVE, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 855-662-6732 or via email at [email protected]
MarketBeat Community Rating for OncoSec Medical (ONCS)
MarketBeat's community ratings are surveys of what our community members think about OncoSec Medical and other stocks. Vote "Outperform" if you believe ONCS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ONCS will underperform the S&P 500 over the long term. You may vote once every thirty days.
OncoSec Medical (NASDAQ:ONCS) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
5 Wall Street analysts have issued ratings and price targets for OncoSec Medical in the last 12 months. Their average twelve-month price target is $4.50, suggesting that the stock has a possible upside of 183.02%. The high price target for ONCS is $5.00 and the low price target for ONCS is $4.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $4.50 | $5.00 | $5.00 | $5.3333 |
| Price Target Upside: | 183.02% upside | 212.50% upside | 204.88% upside | 166.67% upside |
OncoSec Medical (NASDAQ:ONCS) Consensus Price Target History
OncoSec Medical (NASDAQ:ONCS) Analyst Ratings History
Show:
(Data available from 5/20/2016 forward)
OncoSec Medical (NASDAQ:ONCS) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
OncoSec Medical (NASDAQ ONCS) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 5.50%
Institutional Ownership Percentage: 8.84%
OncoSec Medical (NASDAQ ONCS) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 2/6/2018 | Punit Dhillon | President | Buy | 3,000 | $0.88 | $2,640.00 | |  |
| 2/5/2018 | Daniel J O'connor | CEO | Buy | 16,667 | $1.50 | $25,000.50 | 16,667 | |
| 7/31/2017 | Punit Dhillon | Insider | Buy | 3,000 | $0.88 | $2,640.00 | | |
| 1/31/2017 | Punit Dhillon | Insider | Buy | 3,000 | $0.99 | $2,970.00 | | |
| 10/16/2015 | Punit Dhillon | CEO | Buy | 10,000 | $4.25 | $42,500.00 | 100 | |
| 6/10/2015 | Punit Dhillon | CEO | Buy | 2,500 | $6.74 | $16,850.00 | | |
| 3/20/2014 | Anthony E Maida III | Director | Buy | 22,800 | $0.81 | $18,468.00 | | |
| 3/19/2014 | Punit Dhillon | CEO | Buy | 50,000 | $0.80 | $40,000.00 | | |
(Data available from 1/1/2013 forward)
OncoSec Medical (NASDAQ ONCS) News Headlines
| Source: |
|
OncoSec Medical (NASDAQ:ONCS) SEC Filings
This page is loading this company's SEC Filings. Please wait...
OncoSec Medical (NASDAQ:ONCS) Income Statement, Balance Sheet and Cash Flow Statement
OncoSec Medical (NASDAQ ONCS) Stock Chart for Sunday, May, 20, 2018
Loading chart…
